Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Desogestrel, Ethinylestradiol may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Bimizza is a combined oral contraceptive pill ('the Pill'). You take it to prevent pregnancy. This low-dose contraceptive contains two types of female sex hormones, oestrogen and progestogen. These hormones prevent an egg being released from your ovaries so you can't get pregnant. Bimizza also makes the fluid (mucus) in your cervix thicker which makes it more difficult for sperm to enter the womb. Bimizza is a 21-day pill – you take one each day for 21 days, followed by 7 days when you take no pills. The benefits of taking the Pill include:
Bimizza needs to be taken as directed to prevent pregnancy. 2.
e Bimizza tablets
General notes Before you start taking Bimizza you should read the information on blood clots in section 2. It is particularly important to read the symptoms of a blood clot – see section 2 "Blood clots". It's important that you understand the benefits and risks of taking the Pill before you start taking it, or when deciding whether to carry on taking it. Although the Pill is suitable for most healthy women, it isn't suitable for everyone. →Tell your doctor if you have any of the illnesses or risk factors mentioned in this leaflet. Before you start taking the Pill
• •
if you have (or have ever had) a blood clot in a blood vessel of your legs (deep vein thrombosis, DVT), your lungs (pulmonary embolus, PE) or other organs; if you know you have a disorder affecting your blood clotting – for instance, protein C deficiency, protein S deficiency, antithrombin-III deficiency, Factor V Leiden or antiphospholipid antibodies; if you need an operation or if you are off your feet for a long time (see section 'Blood clots'); if you have ever had a heart attack or stroke; if you have (or have ever had) angina pectoris (a condition that causes severe chest pain and may be a first sign of a heart attack) or transient ischaemic attack [TIA -temporary stroke symptoms]). if you have any of the following diseases that may increase your risk of a clot in the arteries: o severe diabetes with blood vessel damage o very high blood pressure o a very high level of fat in the blood (cholesterol or triglycerides) o a condition known as hyperhomocysteinaemia; if you have (or have ever had) a type of migraine called 'migraine with aura'; if you have or have recently had a severe liver disease;
• • • • • • •
if you have ever had a liver tumour; if you have or have had a pancreatitis (an inflammation of the pancreas) associated with high levels of fatty substances in your blood; known or suspected pregnancy; if you have cancer affected by sex hormones – such as some cancers of the breast, womb lining or ovary; if you have vaginal bleeding that has not been explained by your doctor; if you are allergic (hypersensitive) to any of the ingredients in Bimizza. if you have hepatitis C and are taking medicinal products containing ombitasvir/ paritaprevir/ ritonavir, dasabuvir, glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir (see also section "Other medicines and Bimizza").
→If you suffer from any of these, or get them for the first time while taking Bimizza, contact your doctor as soon as possible. Do not take Bimizza. Warnings and precautions When should you contact your doctor? Seek urgent medical attention
If you experience symptoms of angioedema such as swollen face, tongue and/or throat and/or difficulty swallowing or hives potentially with difficulty breathing contact a doctor immediately. Products containing estrogens may cause or worsen the symptoms of hereditary and aquired angioedema.
Tell your doctor if any of the following conditions apply to you. If the condition develops, or gets worse while you are using Bimizza, you should also tell your doctor. •
• • • • • • • • • •
If you have brown patches on your face or body (chloasma) – if so avoid too much exposure to the sun or ultraviolet light. If you have Crohn's disease or ulcerative colitis (chronic inflammatory bowel disease). If you have systemic lupus erythematosus (SLE – a disease affecting your natural defence system). If you have haemolytic uraemic syndrome (HUS – a disorder of blood clotting causing failure of the kidneys). If you have sickle cell anaemia (an inherited disease of the red blood cells). If you have elevated levels of fat in the blood (hypertriglyceridaemia) or a positive family history for this condition. Hypertriglyceridaemia has been associated with an increased risk of developing pancreatitis (inflammation of the pancreas). If you need an operation, or you are off your feet for a long time (see in section 2 'Blood clots'). If you have just given birth you are at an increased risk of blood clots. You should ask your doctor how soon after delivery you can start taking Bimizza (see section The Pill and Thrombosis). If you have an inflammation in the veins under the skin (superficial thrombophlebitis). If you have varicose veins.
The Pill and Thrombosis Blood Clots Using a combined hormonal contraceptive such as Bimizza, increases your risk of developing a blood clot compared with not using one. In rare cases a blood clot can block blood vessels and cause serious problems. Blood clots can develop
What are you possibly suffering from? Deep vein thrombosis
Pulmonary embolism
cold'). Symptoms most commonly occur in one eye:
Retinal vein thrombosis (blood clot in the eye) Heart attack
Stroke
Blood clots blocking other blood vessels
Blood clots in a vein What can happen if a blood clot forms in a vein?
• • •
Out of 10,000 women who are using a combined hormonal contraceptive that contains levonorgestrel, norethisterone, or norgestimate about 5-7 will develop a blood clot in a year. Out of 10,000 women who are using a combined hormonal contraceptive that contains desogestrel such as Bimizza between about 9 and 12 women will develop a blood clot in a year. The risk of having a blood clot will vary according to your personal medical history (see "Factors that increase your risk of a blood clot" below).
Women who are not using a combined hormonal pill/patch/ring and are not pregnant Women using a combined hormonal contraceptive pill containing levonorgestrel, norethisterone or norgestimate Women using Bimizza
Risk of developing a blood clot in a year About 2 out of 10,000 women About 5-7 out of 10,000 women About 9-12 out of 10,000 women
Factors that increase your risk of a blood clot in a vein The risk of a blood clot with Bimizza is small but some conditions will increase the risk. Your risk is higher:
• • • • • • •
if you are overweight; if you have high blood pressure; if a member of your immediate family has had a heart attack or stroke at a young age (less than about 50). In this case you could also have a higher risk of having a heart attack or stroke; if you, or someone in your immediate family, have a high level of fat in the blood (cholesterol or triglycerides); if you get migraines, especially migraines with aura; if you have a problem with your heart (valve disorder, disturbance of the rhythm called atrial fibrillation); if you have diabetes.
If you have more than one of these conditions or if any of them are particularly severe the risk of developing a blood clot may be increased even more. If any of the above conditions change while you are using Bimizza, for example you start smoking, a close family member experiences a thrombosis for no known reason; or you gain a lot of weight, tell your doctor. The pill and cancer The Pill reduces your risk of cancer of the ovary and womb if used in the long term. However, it also seems to slightly increase your risk of cancer of the cervix – although this may be due to having sex without a condom rather than the Pill itself. All women should have regular smear tests. If you have breast cancer, or have had it in the past, you should not take the Pill. The Pill slightly increases your risk of breast cancer. This risk goes up the longer you're on the Pill, but returns to normal within about 10 years of stopping it. Because breast cancer is rare in women under the age of 40 the extra number of cases of breast cancer in current and recent users of the Pill is small. For example:
Psychiatric disorders Some women using hormonal contraceptives including Bimizza have reported depression or depressed mood. Depression can be serious and may sometimes lead to suicidal thoughts. If you experience mood changes and depressive symptoms contact your doctor for further medical advice as soon as possible. Other medicines and Bimizza tablets Tell your doctor, pharmacist or family planning nurse if you are using, have recently used or might use any other medicines or herbal products, even those not prescribed. Also tell any other doctor or dentist who prescribes another medicine (or your pharmacist) that you use Bimizza. This is because Bimizza can also affect how well other medicines work, causing either an increase in effect (e.g., ciclosporin) or a decrease in effect (e.g., lamotrigine). Remind your doctor if you are taking these in case your treatment needs to be adjusted. Also check the leaflets that come with all your medicines to see if they can be taken with hormonal contraceptives. Some medicines may stop Bimizza from working properly. These include medicines used for the treatment of:
If you are taking medicines or herbal products that might make Bimizza less effective, a barrier contraceptive method should also be used. Since the effect of another medicine on Bimizza may last up to 28 days after stopping the medicine, it is necessary to use the additional barrier contraceptive method for that long. Do not use Bimizza tablets if you have Hepatitis C and are taking the medicinal products containing ombitasvir/paritaprevir/ritonavir, dasabuvir, glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir, as these products may cause increases in liver function blood test results (increase in ALT liver enzyme). Your doctor will prescribe another type of contraceptive prior to start of the treatment with these medicinal products. Bimizza tablets can be restarted approximately 2 weeks after completion of this treatment. See the section on "Do not take Bimizza tablets" Ask your doctor or pharmacist for advice before taking any medicine.
Bimizza tablets with food and drink Bimizza tablets may be taken with or without food, with needed amount of water. Laboratory tests: If you need a blood test, tell your doctor or the laboratory staff that you are taking the pill, because hormone contraceptives can affect the results of some tests. Pregnancy and breast-feeding
Do not use Bimizza if you are pregnant. If you think you might be pregnant, do a pregnancy test to confirm that you are before you stop taking Bimizza. Bimizza is not recommended for use during breast-feeding. Ask your doctor or family planning nurse about alternative contraception. Breast-feeding may not stop you getting pregnant. Driving and using machines There is no information suggesting that use of Bimizza tablets affects driving or use of machines. Bimizza tablets contain lactose This product contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before you take this product. Use in adolescents No clinical data on efficacy and safety are available in adolescents below 18 years. 3.
Bimizza tablets
Take one Bimizza tablet every day with required amount of water. Swallow the pill as a whole. Do not chew the pill. You may take the tablets with or without food, but you should take the tablets every day around the same time. The strip contains 21 tablets. Next to each tablet is printed the day of the week that it should be taken. If, for example you start on a Wednesday, take a tablet with "WED" next to it. Follow the direction of the arrow on the strip until all 21 tablets have been taken. Then take no tablets for 7 days. In the course of these 7 tablet-free days (otherwise called a stop or gap week) bleeding should begin. This is so-called "withdrawal bleeding" and it usually starts on the 2nd or 3rd day of the gap week. On the 8th day after the last tablet of Bimizza (that is, after the 7-day gap week), you should start with the following strip, whether your bleeding has stopped or not. This means that you should start every strip on the same day of the week and that the withdrawal bleed should occur on the same days each month. If you use Bimizza tablets in this manner, you are also protected against pregnancy during the 7 days when you are not taking a tablet. When can you start with the first strip? •
If you have not used a contraceptive with hormones in the previous month Begin with Bimizza on the first day of the cycle (that is the first day of your period). If you start Bimizza on the first day of your period you are immediately protected against pregnancy. Or if Your period has already begun start taking Bimizza on day 5 (counting the first day of your period as day 1) whether or not your bleeding has stopped. You must also use extra contraception such as condoms, until you have taken the first seven pills correctly.
•
Changing from a combination hormonal contraceptive, or combination contraceptive vaginal ring or patch You can start Bimizza preferably on the day after the last active tablet (the last tablet containing active substances) of your previous pill, but at the latest on the day after the tablet-free days of your previous pill (or after the last inactive tablet of your previous pill). When changing from a combination contraceptive vaginal ring or patch, follow the advice of your doctor.
•
If you are currently on a 21-day Pill: start taking Bimizza the next day after the end of the previous strip. You will have contraceptive protection with your first pill but you will not have a bleed until after you finish your first strip of Bimizza.
•
If you are currently on a 28-day Pill: start taking Bimizza the day after your last active pill. You will have contraceptive protection with your first pill. You will not have a bleed until after you finish your first strip of Bimizza.
•
Or if you are taking a progestogen-only Pill (mini-Pill or POP): start Bimizza on the first day of bleeding, even if you have already taken the POP for that day. You will have contraceptive cover straight away. If you don't usually have any bleeding while you are taking a progestogen-only Pill, you can stop taking it any day and start Bimizza the next day. You will need to use extra contraception, such as a condom, for seven days.
•
Changing from a progestogen-only-method (, injection, implant or a progestogen-releasing IUD) You may switch any day from the progestogen-only pill (from an implant or an IUD on the day of its removal, from an injectable when the next injection would be due) but in all of these cases use extra protective measures (for example, a condom) for the first 7 days of tablet-taking.
•
After a miscarriage or abortion if you have had a miscarriage or an abortion, your doctor may tell you to start taking Bimizza straight away. This means that you will have contraceptive protection with your first pill.
•
After having a baby
•
If you have just had a baby, ask your doctor for advice about contraception
•
If you are not breast feeding:
•
•
•
If you are breastfeeding and want to start Bimizza tablets (again) after having a baby. Read the section on "Breast feeding". Ask your doctor what to do if you are not sure when to start.
What to do if you forget to take Bimizza tablets
The risk of incomplete protection against pregnancy is greatest if you forget a tablet at the beginning or the end of the strip. Therefore, you should keep to the following rules (see the the diagram below): • More than one tablet forgotten in this strip Contact your doctor. • One tablet forgotten in week 1 Take the forgotten tablet as soon as you remember, even if that means taking two tablets at the same time. Continue taking the tablets at the usual time and use extra precautions for the next 7 days, for example, a condom. If you have had sex in the week before forgetting the tablet you may be pregnant. In that case, contact your doctor.
A lost pill If you lose a pill, Either take the last pill of the strip in place of the lost pill. Then take all the other pills on their proper days. Your cycle will be one day shorter than normal, but your contraceptive protection won't be affected. After your seven pill-free days you will have a new starting day, one day earlier than before. Or if you do not want to change the starting day of your cycle, take a pill from a spare strip. Then take all the other pills from your current strip as usual. You can then keep the opened spare strip in case you lose any more pills.
What to do in case of vomiting or severe diarrhoea If you vomit within 3-4 hours of taking a tablet or you have severe diarrhoea for more than 12 hours, there is a risk that the active substances in the tablet are not fully absorbed into your body. The situation is almost the same as forgetting a tablet. After vomiting or diarrhoea, take another tablet from a reserve strip as soon as possible. If possible take it within 12 hours of when you normally take your pill. If this is not possible or 12 hours have passed, you should follow the advice given under "If you forget to take Bimizza tablets". Talk to your doctor if your stomach upset carries on or gets worse. He or she may recommend another form of contraception. Missed a period – could you be pregnant? Occasionally, you may miss a withdrawal bleed. This could mean that you are pregnant, but that is very unlikely if you have taken your pills correctly. Start your next strip at the normal time. If you think that you might have put yourself at risk of pregnancy (for example, by missing pills or taking other medicines), or if
you miss a second bleed, you should do a pregnancy test. You can buy these from the chemist or get a free test at your family planning clinic or doctors surgery. If you are pregnant, stop taking Bimizza and see your doctor. If you take more Bimizza tablets than you should There are no reports of serious harmful results of taking too many Bimizza tablets. If you take several tablets at once then you may have symptoms of nausea or vomiting or bleeding from the vagina. If you have taken too many Bimizza tablets, or you discover that a child has taken some, consult your doctor or pharmacist. Delay of menstrual period: what you need to know Even though it is not recommended, you can delay your menstrual period by going straight to a new strip of Bimizza Tablets instead of the tablet-free period, and finishing it followed by 7 pill free days. You may experience light or menstruation-like bleeding while using the second strip. After the usual tablet-free period of 7 days, start the next strip. You might ask your doctor for advice before deciding to delay your menstrual period. Changing of the first day of your menstrual period: what you must know If you take the tablets according to the instructions, then your period will begin during the tablet-free week. If you have to change this day, reduce the number of the tablet-free days (but never increase them – 7 is the maximum). For example, if your tablet-free days normally begin on a Friday, and you want to change this to a Tuesday (3 days earlier) start a new strip 3 days earlier than usual. If you make the tablet-free interval very short (for example, 3 days or less) you may not have any bleeding during these days. You may then experience light or menstruation-like bleeding. If you are not sure what to do, consult your doctor. If you want to stop taking Bimizza Tablets You can stop taking Bimizza tablets whenever you want. If you do not want to become pregnant, ask your doctor for advice about other reliable methods of birth control. If you want to become pregnant, stop taking Bimizza tablets and wait for a proper period before trying to become pregnant. your doctor or midwife relies on the date of your last natural period before you get pregnant to tell you when your baby is due. However, it will not cause you or the baby any harm if you get pregnant straight away. If you have any further questions on the use of this product, ask your doctor or pharmacist
4.
Possible side effects
Like all medicines, Bimizza tablets can cause side effects, although not everybody gets them. If you get any side effect, particularly if severe and persistent, or have any change to your health that you think may be due to Bimizza, please talk to your doctor. An increased risk of blood clots in your veins (venous thromboembolism (VTE)) or blood clots in your arteries (arterial thromboembolism (ATE)) is present for all women taking combined hormonal
contraceptives. For more detailed information on the different risks from taking combined hormonal contraceptives please see section 2 ''What you need to know before you take Bimizza'' Serious side effects – see a doctor straight away Contact a doctor immediately if you experience any of the following symptoms of angioedema: swollen face, tongue and/or throat and/or difficulty swallowing or hives potentially with difficulty breathing (see also section "Warnings and precautions"). Signs of deep vein thrombosis include;
Signs of a severe allergic reaction to Bimizza
Common (may affect up to 1 in 10 people):
o o o
stroke; mini-stroke or temporary stroke-like symptoms, known as a transient ischaemic attack (TIA); blood clots in the liver, stomach/intestine, kidneys or eye.
The chance of having a blood clot may be higher if you have any other conditions that increase this risk. (See section 2 for more information on the conditions that increase risk for blood clots and the symptoms of a blood clot.) • • • • • • • • • • • • •
Severe allergic reaction to Bimizza Breast cancer Cancer of the cervix Severe liver problems High blood pressure Gall stones Chorea (a problem with the nervous system causing jerky movements that you can't control) Worsening of systemic lupus erythematosus (SLE; when your immune system attacks your body causing, for example, joint ache and tiredness) Stomach and intestine problems such as pancreatitis; Crohn's disease; ulcerative colitis Worsening of otosclerosis (a hearing problem) Problems with blood sugar Worsening of a rare condition called porphyria Worsening of skin problems, such as brown patches on your face or body (chloasma) blister-like rash, (herpes gestationis)
Unknown (frequency cannot be estimated from the available data):
Before you have any blood tests Tell your doctor or the laboratory staff that you are taking the pill, because oral contraceptives can affect the results of some tests. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
5.
Bimizza tablets
Keep this medicine out of the sight and reach of children. Do not store above 25°C. Store in original package in order to protect from moisture and light. Expiry date Do not use this medicine after the expiry date which is stated on the package after "EXP". The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
What Bimizza tablets contains The active substances are desogestrel and ethinylestradiol. The other ingredients are: All-rac-alpha-tocopherol, potato starch, povidone (E1201), stearic acid (E570), silica colloidal anhydrous (E551) and lactose anhydrous. What Bimizza tablets look like and contents of the pack Each tablet is round, white to off-white, uncoated, biconvex, debossed with '141' on one side and other side plain. Each strip of Bimizza tablets contains 21 white tablets. Each box of Bimizza tablets contains 1, 3 or 6 strips of 21 tablets provided with or without a desiccant. Not all pack sizes may be marketed. Marketing Authorisation Holder Morningside Healthcare Ltd Unit C, Harcourt Way Leicester, LE19 1WP, United Kingdom
Manufacturer Morningside Pharmaceuticals Ltd 5 Pavilion Way, Castle Business Park, Loughborough, Leicestershire, LE11 5GW, United Kingdom This leaflet was last revised in December 2024
Bimizza 150 microgram/20 microgram Tablets comes as tablet containing 150mcg / 20mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Bimizza 150 microgram/20 microgram Tablets is desogestrel, ethinylestradiol.
This leaflet reproduces the patient information leaflet approved for Bimizza 150 microgram/20 microgram Tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Oral contraception
The decision to prescribe Bimizza should take into consideration the individual woman's current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Bimizza compares with other CHCs (see sections 4.3 and 4.4).
Route of administration: Oral use
How to take Bimizza
Tablets must be taken every day at about the same time, with some liquid as needed, in the order shown on the blister pack. One tablet is to be taken daily for 21 consecutive days. Each subsequent pack is started after a 7-day tablet-free interval; during which time a withdrawal bleeding usually occurs. This usually starts on day 2-3 after the last tablet and may not have finished before the next pack is started.
How to start Bimizza
No preceding hormonal contraceptive use (in the past month)
Tablet-taking has to start on day 1 of the woman's natural cycle (i.e. the first day of her menstrual bleeding) in which case no extra contraceptive precaution are necessary.
If menstruation has already begun, (that is 2, 3, or 4 days previously), tablet taking should commence on day 5 of the menstrual period. In this case additional contraceptive precautions must be taken for the first 7 days of tablet taking. If menstruation began more than 5 days previously then the patient should be advised to wait until her next menstrual period before starting to take Bimizza.
Changing from a 21 day pill or another 22 day pill to Bimizza:
All tablets in the old pack should be finished. The first Bimizza tablet is taken the next day i.e. no gap is left between taking tablets nor does the patient need to wait for her period to begin. Tablets should be taken as instructed in 'How to take Bimizza'. Additional contraceptive precautions are not required. The patient will not have a period until the end of the first Bimizza pack, but this is not harmful, nor does it matter if she experiences some bleeding on tablet-taking days.
Changing from a combined Every Day Pill (28 day tablets) to Bimizza:
Bimizza should be started after taking the last active tablet from the 'Every Day Pill' pack (i.e. after taking 21 or 22 tablets). The first Bimizza tablet is taken the next day i.e. no gap is left between taking tablets nor does the patient need to wait for her period to begin. One tablet is taken daily at the same time, without interruption for 21 days, followed by a 7 day tablet-free period. Each subsequent pack is started after the 7 day tablet-free period has elapsed. Additional contraceptive precautions are not required. Remaining tablets from the Every Day (ED) pack should be discarded. The patient will not have a period until the end of the first Bimizza pack, but this is not harmful, nor does it matter if she experiences some bleeding on tablet-taking days.
Changing from a Progestogen -only Pill (POP or Mini Pill) to Bimizza:
The first Bimizza tablet should be taken on the first day of the period, even if the patient has already taken a mini pill on that day. One tablet is taken daily at the same time, without interruption for 21 days, followed by a 7 day tablet-free period. Each subsequent pack is started after the 7 day tablet-free period has elapsed. Additional contraceptive precautions are not then required. All the remaining Progestogen-only pills in the mini pill pack should be discarded. If the patient is taking a (mini) pill, then she may not always have a period, especially when she is breast feeding. The first Bimizza tablet should be taken on the day after stopping the mini pill. All remaining pills in the mini pill packet must be discarded. Additional contraceptive precautions must be taken for the first seven days.
• Changing from a combined hormonal contraceptive (combined oral contraceptive (COC), vaginal ring or transdermal patch)
The woman should start taking Bimizza 150 microgram/20 microgram Tablets preferably on the day after the last active tablet (the last tablet containing the active substances) of her previous COC, but at the latest on the day following the usual tablet-free or placebo tablet interval of her previous COC. In case a vaginal ring or a transdermal patch has been used, the woman should start using Bimizza 150 microgram/20 microgram Tablets preferably on the day of removal, but at the latest when the next application would have been due.
• Changing from a progestogen-only-method (injection, implant) or from a progestogen-releasing intrauterine system (IUS)
The woman may switch any day from the progestogen-only pills (from an implant or the IUS on the day of its removal; from an injectable when the next injection would be due) but should be advised to additionally use a contraceptive precautions for the first 7 days of tablet-taking in all of these cases.
• Following first-trimester abortion
The woman may start immediately. When doing so, she need not take additional contraceptive measures.
• Following delivery or second-trimester abortion
The woman should be advised to start at day 21 to 28 after delivery (non-breast feeding) or second-trimester abortion. When starting later, the woman should be advised to additionally use a barrier method for the first 7 days. However if intercourse has already occurred, pregnancy should be excluded before the actual start of COC use or the woman has to wait for her first menstrual period.
For breastfeeding women - see section 4.6.
Additional contraceptive precautions:
When additional contraceptive precautions are required the patient should be advised either not to have sex, or to use a cap plus spermicide, or for her partner to use a condom. Rhythm methods should not be advised as the pill disrupts the usual cyclical changes associated with the natural menstrual cycle e.g. changes in temperature and cervical mucus.
How to skip a period:
To skip a period, a new pack of Mercilon should be started on the day after finishing the current pack (the patient skips the tablet-free days). Tablet-taking should be continued in the usual way. During the use of the second pack she may experience slight spotting or breakthrough bleeding but contraceptive protection will not be diminished provided there are no tablet omissions. The next pack of Mercilon is started after the usual 7 tablet-free days, regardless of whether the period has completely finished or not.
Management of missed tablets
If the user is less than 12 hours late in taking any tablet, contraceptive protection is not reduced.
The woman should take the tablet as soon as she remembers, and should take further tablets at usual time.
If she is more than 12 hours late in taking any tablet, contraceptive protection may be reduced. The patient should take the last forgotten tablet, even if this means taking two tablets in one day, and then continue to take tablets at the normal time. Additional contraceptive precautions should be taken for the next seven days. The management of missed tablets can be guided by the following two basic rules:
1. tablet-taking must never be discontinued for longer than 7 days
2. 7 days of uninterrupted tablet-taking are required to attain adequate suppression of the hypothalamus-pituitary-ovarian-axis.
Accordingly the following advice can be given in daily practice:
• Week 1
The user should take the last missed tablet as soon as she remembers, even if this means taking two tablets at the same time. She then continues to take tablets at her usual time. In addition, a barrier method such as a condom should be used for the next 7 days. If intercourse took place in the preceding 7 days, the possibility of a pregnancy should be considered. The more tablets are missed and the closer they are to the regular tablet-free interval, the higher the risk of a pregnancy.
• Week 2
The user should take the last missed tablet as soon as she remembers, even if this means taking two tablets at the same time. She then continues to take tablets at her usual time. Provided that the woman has taken her tablets correctly in the 7 days preceding the first missed tablet, there is no need to use extra contraceptive precautions. However, if she has missed more than 1 tablet, the woman should be advised to use extra precautions for 7 days.
• Week 3
The risk of reduced reliability is imminent because of the forthcoming 7-day tablet-free interval. However, by adjusting the tablet-intake schedule, reduced contraceptive protection can still be prevented. By adhering to either of the following two options, there is therefore no need to use extra contraceptive precautions, provided that in the 7 days preceding the first missed tablet the woman has taken all tablets correctly. If this is not the case, she should follow the first of these two options and use extra precautions for the next 7 days as well.
1. The user should take the last missed tablet as soon as she remembers, even if this means taking two tablets at the same time. She then continues to take tablets at her usual time. The next blister pack must be started as soon as the current blister pack is finished, i.e., no gap should be left between packs. The user is unlikely to have a withdrawal bleed until the end of the second pack, but she may experience spotting or breakthrough bleeding on tablet-taking days.
2. The woman may also be advised to discontinue tablet-taking from the current blister pack. She should then have a tablet-free interval of up to 7 days, including the days she missed tablets, and subsequently continue with the next blister pack.
If the woman missed tablets and subsequently has no withdrawal bleed in the first normal tablet-free interval, the possibility of a pregnancy should be considered.
Advice in case of gastro-intestinal disturbances
In case of severe gastro-intestinal disturbances (e.g., vomiting or diarrhoea), absorption may not be complete and additional contraceptive measures should be taken. Unless diarrhoea is extremely severe, it does not affect steroidal absorption.
If vomiting occurs within 3-4 hours after tablet-taking, a new (replacement) tablet should be taken as soon as possible. The new tablet should be taken within 12 hours of the usual time of tablet-taking if possible. If more than 12 hours elapse, the advice concerning missed tablets, under section “Management of missed tablets”, is applicable. If the woman does not want to change her normal tablet-taking schedule, she has to take the extra tablet(s) from another blister pack.
How to postpone a withdrawal bleed
To delay a period the woman should continue with another blister pack of Bimizza 150 microgram/20 microgram Tablets without a tablet-free interval. The extension can be carried on for as long as wished until the end of the second pack. During the extension the woman may experience breakthrough-bleeding or spotting. Regular intake of Bimizza 150 microgram/20 microgram Tablets is then resumed after the usual 7-day tablet-free interval.
To shift her periods to another day of the week than the woman is used to with her current scheme, she can be advised to shorten her forthcoming tablet-free interval by as many days as she likes. The shorter the interval, the higher the risk that she does not have a withdrawal bleed and will experience breakthrough-bleeding and spotting during the subsequent pack (just as when delaying a period).
Paediatric population
The safety and efficacy of desogestrel in adolescents below 18 years has not yet been established. No data are available.
Combined hormonal contraceptives (CHCs) should not be used in the presence of any of the conditions listed below. Should any of the conditions appear for the first during CHC use, the product should be stopped immediately.
• Presence or risk of venous thromboembolism (VTE)
o Venous thromboembolism – current VTE (on anticoagulants) or history of (e.g. deep venous thrombosis [DVT] or pulmonary embolism [PE]).
o Known hereditary or acquired predisposition for venous thromboembolism, such as APC-resistance, (including Factor V Leiden), antithrombin-III-deficiency, protein C deficiency, protein S deficiency.
o Major surgery with prolonged immobilisation (see section 4.4).
o A high risk of venous thromboembolism due to the presence of multiple risk factors (see section 4.4).
• Presence or risk of arterial thromboembolism (ATE)
o Arterial thromboembolism – current arterial thromboembolism, history of arterial thromboembolism (e.g. myocardial infarction) or prodromal condition (e.g. angina pectoris)
o Cerebrovascular disease – current stroke, history of stroke or prodromal condition (e.g. transient ischaemic attack, TIA).
o Known hereditary or acquired predisposition for arterial thromboembolism, such as hyperhomocysteinaemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant).
o History of migraine with focal neurological symptoms.
o A high risk of arterial thromboembolism due to multiple risk factors (see section 4.4) or to the presence of one serious risk factor such as:
• diabetes mellitus with vascular symptoms
• severe hypertension
• severe dyslipoproteinaemia
• Pancreatitis or a history thereof if associated with severe hypertriglyceridemia.
• Presence or history of severe hepatic disease as long as liver function values have not returned to normal.
• Presence or history of liver tumours (benign or malignant).
• Known or suspected estrogen-dependent tumours, (See 4.4 Special warnings and special precautions for use: The Pill and Cancer).
• Endometrial hyperplasia.
• Undiagnosed vaginal bleeding.
• Known or suspected pregnancy.
• Hypersensitivity to the active substances or to any of the excipients of Bimizza 150 microgram/20 microgram Tablets listed in section 6.1.
Bimizza is contraindicated for concomitant use with the medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir, medicinal products containing glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir (see section 4.5).
If any of the conditions or risk factors mentioned below is present, the suitability of Bimizza should be discussed with the woman.
In the event of aggravation, or first appearance of any of these conditions or risk factors, the woman should be advised to contact her doctor to determine whether the use of Bimizza should be discontinued.
Circulatory disorders
Risk of venous thromboembolism (VTE)
The use of any combined hormonal contraceptive (CHC) carries an increased risk of venous thromboembolism (VTE) compared with no use. Products that contain levonorgestrel, norgestimate or norethisterone are associated with the lowest risk of VTE. Other products such as Bimizza may have up to twice this level of risk. The decision to use any product other than one with the lowest VTE risk should be taken only after a discussion with the woman to ensure she understands the risk of VTE with Bimizza, how her current risk factors influence this risk, and that her VTE risk is highest in the first ever year of use. There is also some evidence that the risk is increased when a CHC is re-started after a break in use of 4 weeks or more.
In women who do not use a CHC and are not pregnant about 2 out of 10,000 will develop a VTE over the period of one year. However, in any individual woman the risk may be far higher, depending on her underlying risk factors (see below).
It is estimated1 that out of 10,000 women who use a CHC containing desogestrel between 9 and 12 women will develop a VTE in one year; this compares with about 62 in women who use a levonorgestrel-containing CHC.
In both cases, the number of VTEs per year is fewer than the number expected during pregnancy or in the postpartum period.
VTE may be fatal in 1-2% of cases.
1 These incidences were estimated from the totality of the epidemiological study data, using relative risks for the different products compared with levonorgestrel-containing CHCs.
2 Mid-point of range of 5-7 per 10,000 WY, based on a relative risk for CHCs containing levonorgestrel versus non-use of approximately 2.3 to 3.6
Extremely rarely, thrombosis has been reported to occur in CHC users in other blood vessels, e.g. hepatic, mesenteric, renal or retinal veins and arteries.
Risk factors for VTE
The risk for venous thromboembolic complications in CHC users may increase substantially in a woman with additional risk factors, particularly if there are multiple risk factors (see table).
Bimizza is contraindicated if a woman has multiple risk factors that put her at high risk of venous thrombosis (see section 4.3). If a woman has more than one risk factor, it is possible that the increase in risk is greater than the sum of the individual factors – in this case her total risk of VTE should be considered. If the balance of benefits and risks is considered to be negative a CHC should not be prescribed (see section 4.3).
Table: Risk factors for VTE
Risk factor
Comment
Obesity (body mass index over 30 kg/m2)
Risk increases substantially as BMI rises.
Particularly important to consider if other risk factors also present.
Prolonged immobilisation, major surgery, any surgery to the legs or pelvis, neurosurgery, or major trauma
Note: Temporary immobilisation including air travel >4 hours can also be a risk factor for VTE, particularly in women with other risk factors.
In these situations it is advisable to discontinue use of the patch/pill/ring (in the case of elective surgery at least four weeks in advance) and not resume until two weeks after complete remobilisation. Another method of contraception should be used to avoid unintentional pregnancy.
Antithrombotic treatment should be considered if Bimizza has not been discontinued in advance.
Positive family history (venous thromboembolism ever in a sibling or parent especially at a relatively early age e.g. before 50).
If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any CHC use.
Other medical conditions associated with VTE
Cancer, systemic lupus erythematosus, haemolytic uraemic syndrome, chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis) and sickle cell disease
Increasing age
Particularly above 35 years
There is no consensus about the possible role of varicose veins and superficial thrombophlebitis in the onset or progression of venous thrombosis.
The increased risk of thromboembolism in pregnancy, and particularly the 6-week period of the puerperium, must be considered (for information on “Pregnancy and lactation” see section 4.6).
Symptoms of VTE (deep vein thrombosis and pulmonary embolism)
In the event of symptoms women should be advised to seek urgent medical attention and to inform the healthcare professional that she is taking a CHC.
Symptoms of deep vein thrombosis (DVT) can include:
o unilateral swelling of the leg and/or foot or along a vein in the leg;
o pain or tenderness in the leg which may be felt only when standing or walking;
o increased warmth in the affected leg; red or discoloured skin on the leg.
Symptoms of pulmonary embolism (PE) can include:
o sudden onset of unexplained shortness of breath or rapid breathing;
o sudden coughing which may be associated with haemoptysis;
o sharp chest pain;
o severe light headedness or dizziness;
o rapid or irregular heartbeat.
Some of these symptoms (e.g. “shortness of breath”, “coughing”) are non-specific and might be misinterpreted as more common or less severe events (e.g. respiratory tract infections).
Other signs of vascular occlusion can include: sudden pain, swelling and slight blue discoloration of an extremity.
If the occlusion occurs in the eye symptoms can range from painless blurring of vision which can progress to loss of vision. Sometimes loss of vision can occur almost immediately.
Risk of arterial thromboembolism (ATE)
Epidemiological studies have associated the use of CHCs with an increased risk for arterial thromboembolism (myocardial infarction) or for cerebrovascular accident (e.g. transient ischaemic attack, stroke). Arterial thromboembolic events may be fatal.
Risk factors for ATE
The risk of arterial thromboembolic complications or of a cerebrovascular accident in CHC users increases in women with risk factors (see table). Bimizza is contraindicated if a woman has one serious or multiple risk factors for ATE that puts her at high risk of arterial thrombosis (see section 4.3). If a woman has more than one risk factor, it is possible that the increase in risk is greater than the sum of the individual factors - in this case her total risk should be considered. If the balance of benefits and risks is considered to be negative a CHC should not be prescribed (see section 4.3).
Risk factor
Comment
Increasing age
Particularly above 35 years
Smoking
Women should be advised not to smoke if they wish to use a CHC. Women over 35 who continue to smoke should be strongly advised to use a different method of contraception.
Hypertension
Obesity (body mass index over 30 kg/m2)
Risk increases substantially as BMI increases.
Particularly important in women with additional risk factors.
Positive family history (arterial thromboembolism ever in a sibling or parent especially at a relatively early age e.g. below 50).
If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any CHC use.
Migraine
An increase in frequency or severity of migraine during CHC use (which may be prodromal of a cerebrovascular event) may be a reason for immediate discontinuation.
Other medical conditions associated with adverse vascular events
Diabetes mellitus, hyperhomocysteinaemia, valvular heart disease and atrial fibrillation, dyslipoproteinaemia and systemic lupus erythematosus.
Symptoms of ATE
In the event of symptoms women should be advised to seek urgent medical attention and to inform the healthcare professional that she is taking a CHC.
Symptoms of a cerebrovascular accident can include:
o sudden numbness or weakness of the face, arm or leg, especially on one side of the body;
o sudden trouble walking, dizziness, loss of balance or coordination;
o sudden confusion, trouble speaking or understanding;
o sudden trouble seeing in one or both eyes;
o sudden, severe or prolonged headache with no known cause;
o loss of consciousness or fainting with or without seizure.
Temporary symptoms suggest the event is a transient ischaemic attack (TIA).
Symptoms of myocardial infarction (MI) can include:
pain, discomfort, pressure, heaviness, sensation of squeezing or fullness in thechest, arm, or below the breastbone;
o discomfort radiating to the back, jaw, throat, arm, stomach;
o feeling of being full, having indigestion or choking;
o sweating, nausea, vomiting or dizziness;
o extreme weakness, anxiety, or shortness of breath;
o rapid or irregular heartbeats.
Tumours
An increased risk of cervical cancer in long-term users of COCs (> 5 years) has been reported in some epidemiological studies, but there continues to be controversy about the extent to which this finding is attributable to the confounding effects of sexual behaviour and other factors such as human papilloma virus (HPV).
A meta-analysis from 54 epidemiological studies reported that there is a slightly increased relative risk (RR = 1.24) of having breast cancer diagnosed in women who are currently using COCs. The observed pattern of increased risk may be due to an earlier diagnosis of breast cancer in COC users, the biological effects of COCs or a combination of both. The additional breast cancers diagnosed in current users of COCs or in women who have used COCs in the last ten years are more likely to be localised to the breast than those in women who never used COCs.
Breast cancer is rare among women under 40 years of age whether or not they take COCs. Whilst this background risk increases with age, the excess number of breast cancer diagnoses in current and recent COC users is small in relation to the overall risk of breast cancer (see bar chart).
The most important risk factor for breast cancer in COC users is the age women discontinue the COC; the older the age at stopping, the more breast cancers are diagnosed. Duration of use is less important and the excess risk gradually disappears during the course of the 10 years after stopping COC use such that by 10 years there appears to be no excess.
The possible increase in risk of breast cancer should be discussed with the user and weighed against the benefits of COCs taking into account the evidence that they offer substantial protection against the risk of developing certain other cancers (e.g. ovarian and endometrial cancer).
In rare cases, benign liver tumours, and even more rarely malignant liver tumours have been reported in users of CHCs. In isolated cases, these tumours have led to life-threatening intra-abdominal haemorrhages. A hepatic tumour should be considered in the differential diagnosis when severe upper abdominal pain, liver enlargement or signs of intra-abdominal haemorrhage occur in women taking CHCs.
With the use of the higher-dosed COCs (50 μg ethinylestradiol) the risk of endometrial and ovarian cancer is reduced. Whether this also applies to lower-dosed COCs remains to be confirmed.
Other conditions
Women with hypertriglyceridaemia or a family history thereof may be at increased risk of pancreatitis when using CHCs.
Although small increases in blood pressure have been reported in many women taking CHCs, clinically relevant increases are rare. Only in these rare cases an immediate discontinuation of CHC use is justified. A systematic relationship between CHC use and clinical hypertension has not been established. If, during the use of a CHC in pre-existing hypertension, constantly elevated blood pressure values or a significant increase in blood pressure do not respond adequately to antihypertensive treatment, the CHC must be withdrawn. Where considered appropriate, CHC use may be resumed if normotensive values can be achieved with antihypertensive therapy.
However, if a sustained clinically significant hypertension develops during the use of a CHC then it is prudent for the physician to withdraw the CHC and treat the hypertension.
The following conditions have been reported to occur or deteriorate with both pregnancy and CHC use, but the evidence of an association with CHC use is inconclusive: Jaundice and/or pruritus related to cholestasis; gallstone formation; porphyria; systemic lupus erythematosus; haemolytic uraemic syndrome; Sydenham's chorea; herpes gestationis; otosclerosis-related hearing loss.
Exogenous estrogens may induce or exacerbate symptoms of hereditary and acquired angioedema.
Acute or chronic disturbances of liver function may necessitate discontinuation of CHC use until markers of liver function return to normal. Recurrence of cholestatic jaundice which previously occurred during pregnancy or during previous use of sex steroids necessitates the discontinuation of CHCs.
Although CHCs may have an effect on peripheral insulin resistance and glucose tolerance, there is no evidence for a need to alter the therapeutic regimen in diabetics using low-dose CHCs (containing <0.05 mg ethinylestradiol). However, diabetic women should be carefully observed, particularly in the early stage of CHC use.
Crohn's disease and of ulcerative colitis has been reported during CHC use.
Chloasma may occasionally occur, especially in women with a medical history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to sunlight or ultra-violet radiation whilst taking CHCs.
Bimizza contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Relative Contraindications
Severe depression or a history of this condition.
Depressed mood and depression are well-known undesirable effects of hormonal contraceptive use (see section 4.8). Depression can be serious and is a well-known risk factor for suicidal behaviour and suicide. Women should be advised to contact their physician in case of mood changes and depressive symptoms, including shortly after initiating the treatment.
Medical examination/consultation
Prior to the initiation or reinstitution of Bimizza a complete medical history (including family history) should be taken and pregnancy must be ruled out. Blood pressure should be measured and a physical examination should be performed, guided by the contra-indications (see section 4.3) and warnings (see section 4.4). It is important to draw a woman's attention to the information on venous and arterial thrombosis, including the risk of Bimizza compared with other CHCs, the symptoms of VTE and ATE, the known risk factors and what to do in the event of a suspected thrombosis.
The woman should also be instructed to carefully read the user leaflet and to adhere to the advice given. The frequency and nature of examinations should be based on established practice guidelines and be adapted to the individual woman.
Women should be advised that hormonal contraceptives do not protect against HIV infections (AIDS) and other sexually transmitted diseases. If there is risk of STI/HIV (including during pregnancy or postpartum), the correct and consistent use of condoms is recommended, either alone or with another contraceptive method.
Reduced efficacy
The efficacy of Bimizza may be reduced in the event of missed tablets (section 4.2.), gastro-intestinal disturbances (section 4.2.) or concomitant medication that decrease the plasma concentration of etonogestrel, the active metabolite of desogestrel (section 4.5.).
Reduced cycle control/irregular bleeding
With all CHCs, irregular bleeding (spotting and breakthrough bleeding) may occur, especially during the first months of use. Therefore, the evaluation of any irregular bleeding is only meaningful after an adaptation interval of about 3 cycles.
If bleeding irregularities persist or occur after previously regular cycles, then non-hormonal causes should be considered and adequate diagnostic measures are indicated to exclude malignancy or pregnancy. These may include curettage.
In some women withdrawal bleeding may not occur during the tablet-free interval. If the CHC has been taken according to the directions described in section 4.2, it is unlikely that the woman is pregnant. However, if the CHC has not been taken according to these directions prior to the first missed withdrawal bleed or if two withdrawal bleeds are missed, pregnancy must be ruled out before CHC use is continued.
Influence of other medical products on Bimizza Tablets
Interactions between oral contraceptives and other medicinal products may lead to breakthrough bleeding and/or contraceptive failure. The following interactions have been reported in the literature.
Hepatic metabolism:
Interactions can occur with medicinal or herbal products that induce microsomal enzymes, specifically cytochrome P450 enzymes (CYP), which can result in increased clearance reducing plasma concentrations of sex hormones and may decrease the effectiveness of combined oral contraceptives, including Bimizza. These products include phenytoin, phenobarbital, primidone, bosentan, carbamazepine, rifampicin, rifabutin and possibly also oxcarbazepine, modafinil, topiramate, felbamate, griseofulvin, some HIV protease inhibitors (e.g., ritonavir) and non-nucleoside reverse transcriptase inhibitors (e.g., efavirenz) and products containing the herbal remedy St. John's wort.
Enzyme induction can occur after a few days of treatment. Maximal enzyme induction is generally observed within a few weeks. After drug therapy is discontinued, enzyme induction can last for about 28 days.
Women receiving any of the above mentioned hepatic enzyme-inducing medicinal or herbal products should be advised that the efficacy of Bimizza may be reduced. A barrier contraceptive method should be used in addition to Bimizza during administration of the hepatic enzyme-inducing medicinal product, and for 28 days after discontinuation of the hepatic enzyme-inducing medicinal product. If concomitant drug administration runs beyond the end of the tablets in the current COC pack, the next COC pack should be started right away without the usual tablet-free interval.
For women on long-term therapy with enzyme-inducing medicinal products, an alternative method of contraception unaffected by enzyme-inducing medicinal products should be considered.
- When co-administered with hormonal contraceptives, many combinations of HIV protease inhibitors (e.g., nelfinavir) and non-nucleoside reverse transcriptase inhibitors (e.g., nevirapine), and/or combinations with Hepatitis C virus (HCV) medicinal products (e.g., boceprevir, telaprevir), can increase or decrease plasma concentrations of progestins, including etonogestrel, the active metabolite of desogestrel, or estrogens. The net effect of these changes may be clinically relevant in some cases.
- Concomitant administration of strong (e.g., ketoconazole, itraconazole, clarithromycin) or moderate (e.g., fluconazole, diltiazem, erythromycin) CYP3A4 inhibitors may increase the serum concentrations of estrogens or progestins, including etonogestrel, the active metabolite of desogestrel.
-Oral contraceptives may interfere with the metabolism of certain other active substances. Accordingly, plasma and tissue concentrations may either increase (e.g. cyclosporin) or decrease (e.g. lamotrigine).
Note: The prescribing information of concomitant medications should be consulted to identify potential interactions.
Pharmacodynamic interactions
During clinical trials with patients treated for hepatitis C virus infections (HCV) with medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin, transaminase (ALT) elevations higher than 5 times the upper limit of normal (ULN) occurred significantly more frequently in women using ethinylestradiol-containing medications such as combined hormonal contraceptives (CHCs). Additionally, also in patients treated with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir, ALT elevations were observed in women using ethinylestradiol-containing medications such as CHCs (see section 4.3).
Therefore, Bimizza users must switch to an alternative method of contraception (e.g., progestagen-only contraception or non-hormonal methods) prior to starting therapy with these combination drug regimens. Bimizza can be restarted 2 weeks following completion of treatment with these combination drug regimens.
Laboratory tests
The use of contraceptive steroids may influence the results of certain laboratory tests, including biochemical parameters of liver, thyroid, adrenal and renal function; plasma levels of (carrier) proteins, e.g. corticosteroid-binding globulin and lipid/lipoprotein fractions, parameters of carbohydrate metabolism and parameters of coagulation and fibrinolysis. Changes generally remain within the normal laboratory range.
Bimizza is not indicated for use during pregnancy.If pregnancy occurs during the use of Bimizza the preparation should be withdrawn immediately.
However, most epidemiological studies have revealed neither an increased risk of birth defects in children born to women who used CHCs prior to pregnancy, nor a teratogenic effect when CHCs were taken inadvertently during early pregnancy.
The increased risk of VTE during the postpartum period should be considered when re-starting Bimizza (see sections 4.2 and 4.4).
Lactation may be influenced by CHCs as they may reduce the quantity and change the composition of breast milk. Therefore, the use of CHCs should generally not be recommended until the breast-feeding mother has completely weaned her child. Small amounts of the contraceptive steroids and/or their metabolites may be excreted with the milk but there is no evidence that this adversely affects infant health.
Fertility
No relevant supporting data/evidence is available to suggest short or long term infertility effects of this product. However, in patients receiving similar oral contraceptive products, an adverse reaction of temporary infertility after discontinuance of treatment has been seen infrequently.
No effects on ability to drive and use machines have been observed
Description of selected adverse reactions
As with all COCs, changes in vaginal bleeding patterns may occur, especially during the first months of use. These may include changes in bleeding frequency (absent, less, more frequent or continuous), intensity (reduced or increased) or duration.
An increased risk of arterial and venous thrombotic and thromboembolic events, including myocardial infarction, stroke, transient ischaemic attacks, venous thrombosis and pulmonary embolism has been observed in women using CHCs, which are discussed in more detail in section 4.4.
Possibly related undesirable effects that have been reported in users of Bimizza or CHC users in general are listed in the table below1. All ADRs are listed by system organ class and frequency; common (≥1/100) , uncommon (≥1/1,000 to < 1/100), and rare (<1/1000) and not known (cannot be estimated from the available data).
Organ systems
common
Uncommon
Rare
Not Known
Immune system disorders
Hypersensitivity
Exacerbation of symptoms of hereditary and acquired angioedema.
Metabolism and nutrition disorders
Fluid retention
Psychiatric disorders
Depressed mood, mood altered
Libido decreased
Libido increased
Nervous system disorders
Headache
Migraine
Eye disorders
Contact lens Intolerance
Vascular disorders
Venous thromboembolism2
Arterial thromboembolism2
Gastrointestinal disorders
Nausea, abdominal pain
Vomiting
diarrhoea
Hepatobiliary disorders
Transaminases increased
Skin and subcutaneous tissue disorders
Rash
Urticaria
Erythema Nodosum, Erythema multiforme
Reproductive system and breast disorders
Breast pain, breast tenderness
Breast enlargement
Vaginal Discharge, Breast discharge
Investigations
Weight increased
Weight decreased
1 The most appropriate MedDRA term (version 11) to describe a certain adverse reaction is listed.
Synonyms or related conditions are not listed,but should be taken into account as well.
2 Incidence in observational cohort studies of ≥1/10000 to 1/1000 women-years.
There have been no reports of serious deleterious effects from overdose.Symptoms that may possibly occur in this case are: nausea, vomiting and slight vaginal bleeding. There are no antidotes and further treatment should be symptomatic.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
⚠ Not the same combination. This medicine contains Desogestrel, Ethinylestradiol. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Bimizza 150 microgram/20 microgram Tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.